China plans to optimize how innovative and essential medicines are reviewed and approved under its Five-Year Plan

China plans to optimize how innovative and essential medicines are reviewed and approved under its Five-Year Plan

China has introduced regulatory reforms to streamline the approval of innovative and essential medicines, aligning with its Five-Year Plan goals to enhance healthcare innovation and global competitiveness. The National Medical Products Administration (NMPA) launched a nationwide 30-day Investigational New Drug (IND) pathway for innovative medicines in 2025, following a successful one-year pilot. This initiative accelerates early-stage clinical trial approvals, reducing time-to-market for novel therapies. Concurrently, the NMPA revised policies to optimize localized production of imported medical devices, expanding eligibility for foreign firms to establish domestic manufacturing under relaxed quality management system (QMS) equivalence criteria. These changes aim to reduce redundant documentation and attract foreign investment while maintaining safety standards.

To protect intellectual property, the NMPA proposed draft measures granting data exclusivity for clinical trials: six years for innovative drugs and three years for improved or first-to-market generics. This addresses prior gaps in data protection, which had enabled rapid generic competition for originator drugs like Novo Nordisk’s Semaglutide. However, ambiguities remain in defining "first overseas approval", potentially complicating strategic planning for multinational firms.

A 2024 study of 167 innovative drugs approved by the NMPA revealed growing domestic R&D capabilities, particularly in oncology, though challenges persist. While expedited programs reduced clinical development times, review delays and reliance on surrogate endpoints—common in 63% of approvals—raise concerns about long-term efficacy validation. Additionally, the State Administration for Market Regulation (SAMR) finalized anti-corruption guidelines and anti-monopoly rules targeting the pharmaceutical sector, addressing practices like pay-for-delay settlements and unfair pricing.

These reforms signal China’s commitment to global regulatory alignment but highlight the need for continued capacity-building and transparency to sustain innovation-driven growth.